* WAVE Life Sciences Ltd WVE.OQ reported a quarterly
adjusted
loss of 15 cents per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -47 cents. The mean expectation of
seven analysts for the quarter was for a loss of 23 cents per
share. Wall Street expected results to range from -43 cents to 2
cents per share.
* Revenue rose 2,245.1% to $29.06 million from a year ago;
analysts expected $19.86 million.
* WAVE Life Sciences Ltd's reported EPS for the quarter was
a loss
of 15 cents.
* The company reported a quarterly loss of $16.26 million.
* WAVE Life Sciences Ltd shares had fallen by 5.1% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 0.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for WAVE Life
Sciences Ltd is $8.00
This summary was machine generated from LSEG data March 6 at
02:42 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.23 -0.15 Beat
Sep. 30 2023 -0.18 0.07 Beat
Jun. 30 2023 -0.33 -0.20 Beat
Mar. 31 2023 -0.04 -0.27 Missed